Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating)'s share price rose 0.3% on Tuesday . The company traded as high as $12.47 and last traded at $11.58. Approximately 64,816 shares were traded during mid-day trading, an increase of 348% from the average daily volume of 14,469 shares. The stock had previously closed at $11.55.

Wall Street Analyst Weigh In

ACRV has been the subject of a number of analyst reports. Piper Sandler initiated coverage on shares of Acrivon Therapeutics in a research report on Sunday, December 11th. They issued an "overweight" rating and a $25.00 price objective for the company. Cowen initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set an "outperform" rating for the company. Jefferies Financial Group initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set a "buy" rating and a $17.00 price target for the company. Finally, Cowen initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set an "outperform" rating for the company.

Acrivon Therapeutics Trading Up 0.3 %

Insider Activity at Acrivon Therapeutics

In other Acrivon Therapeutics news, major shareholder Ltd Chione acquired 400,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The stock was bought at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the purchase, the insider now owns 3,856,597 shares in the company, valued at $48,207,462.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Acrivon Therapeutics news, major shareholder Ltd Chione acquired 400,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The stock was bought at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the purchase, the insider now owns 3,856,597 shares in the company, valued at $48,207,462.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were acquired at an average cost of $12.50 per share, with a total value of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at approximately $54,802,575. The disclosure for this purchase can be found here.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).

Read More

• Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
• Mobileye Expects $17.5 Billion Future For Its Driver Assist Tech
• Is Salesforce's New Rally The Beginning Of A Big Uptrend?
• Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
• Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
• The WD-40 Company Is Ready To Rebound, But Will It?

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.